Cyclopentolate (hydrochloride)
(Synonyms: 盐酸环喷托酯,DL-Cyclopentolate hydrochloride) 目录号 : GC43347
A muscarinic receptor antagonist
Cas No.:5870-29-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Cyclopentolate is an antagonist of muscarinic acetylcholine receptors (Kis = 1.62, 27.5, and 2.63 nM for M1, M2, and M3 receptors, respectively). It inhibits carbachol-induced contraction of isolated human iris sphincter, circular ciliary muscle, and longitudinal ciliary muscle (Kbs = 7.9, 15.8, and 12.5 nM, respectively). Formulations containing cyclopentolate have been used to induce pupil dilation and to prevent the eye from accommodating for near vision.
| Cas No. | 5870-29-1 | SDF | |
| 别名 | 盐酸环喷托酯,DL-Cyclopentolate hydrochloride | ||
| Canonical SMILES | O=C(OCCN(C)C)C(C1(O)CCCC1)C2=CC=CC=C2.Cl | ||
| 分子式 | C17H25NO3•HCl | 分子量 | 327.9 |
| 溶解度 | DMSO: Slightly Soluble,Methanol: Slightly Soluble | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.0497 mL | 15.2486 mL | 30.4971 mL |
| 5 mM | 0.6099 mL | 3.0497 mL | 6.0994 mL |
| 10 mM | 0.305 mL | 1.5249 mL | 3.0497 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
1% Cyclopentolate hydrochloride: another look at the time course of cycloplegia using an objective measure of the accommodative response
Optom Vis Sci 1993 Aug;70(8):651-65.PMID:8414387DOI:10.1097/00006324-199308000-00013.
The time course of cycloplegia was measured by monitoring residual accommodation after the application of 1 drop (29.3 microliters) of 1% Cyclopentolate hydrochloride. Three different measures of residual accommodation were made, one objective assessment with an optometer, and two subjective assessments similar to those used by previous investigators. Pupil diameter was also measured in a subgroup of individuals to compare the time course of the induced mydriasis to that of the cycloplegia. When residual accommodation is measured objectively, maximum cycloplegia occurs 10 min after the application of 1% Cyclopentolate hydrochloride in individuals with light irides. This result suggests that the standard clinical protocol of delaying refraction 30 to 60 min after the application of Cyclopentolate hydrochloride may be too conservative for individuals with light irides. For individuals with dark irides, 30 to 40 min is required for maximum cycloplegia, and the magnitude of residual accommodation in these individuals is similar to that found in light iris individuals at 10 min. When subjective measures are used to estimate residual accommodation, more accommodation is present and the time at which maximum cycloplegia occurs is delayed for individuals with light irides. These results are in agreement with previous studies using subjective techniques. Regardless of iris color or measurement method, the time course for pupil dilation is not the same as the time course for cycloplegia.
Effects of Cyclopentolate hydrochloride Dosage on Anterior Segment Parameters in Young Adults (Measured with Pentacam)
Clin Ophthalmol 2021 Mar 1;15:891-898.PMID:33688157DOI:10.2147/OPTH.S291991.
Purpose: To assess the effects of 0.5% and 1% Cyclopentolate on the main parameters of the anterior segment (central corneal thickness (CCT), anterior chamber angle (ACA), depth (ACD) and volume (ACV)) in low/moderate myopia and hyperopia along with the effect on IOP. Patients and methods: Both eyes of 30 subjects (15 myopic and 15 hyperopic) with mean age±standard deviation of 21.4±3.6 years were enrolled. Each participant was administered two drops of Cyclopentolate 1% in the right eye and two drops of Cyclopentolate 0.5% in the left eye, 15 minutes apart. All participants underwent intraocular pressure (IOP) measurement using noncontact tonometry, and anterior chamber parameter measurement using Pentacam. Results: Following the use of 0.5% and 1% Cyclopentolate among the hyperopic group, there was a statistically significant increase in ACD for 1% (pre 2.762±0.28 mm and post 2.89±0.25 mm) and 0.5% (pre 2.71±0.28 and post 2.86±0.27 mm) and ACV for 1% (pre 141.40±20.59 mm3 and post 154.35±19.69 mm3) and 0.5% (pre 137.40±20.48 mm3 and post 152.93±20.50 mm3). In contrast, ACA decreased with both doses 1% and 0.5%, but was not statistically significant (p for both >0.05%). With 0.5% and 1% Cyclopentolate among the myopia group, there was a significant increase in ACD following Cyclopentolate 1% (pre 3.18±0.22 mm and post 3.25±0.21 mm) and 0.5% (pre 3.200±0.22 mm and post 3.26±0.05 mm), p˂0.05. The ACV was significantly increased following 1% Cyclopentolate, p˂0.001. The ACA showed a statistically significant decrease following Cyclopentolate 1%, P=0.01, but not a significant decrease after Cyclopentolate 0.5%, P=0.170. There was a significant increase in the IOP after 1%, p˂0.001, while a decrease with 0.5%, p=0.008. Conclusion: A topical dosage of Cyclopentolate 1% showed significant changes in ACA and ACV among the hyperopia and myopic groups compared to 0.5%. Therefore, it is important to consider the use of a 0.5% Cyclopentolate dosage to minimize changes to anterior chamber parameters.
Possible allergic reactions to Cyclopentolate hydrochloride: case reports with literature review of uses and adverse reactions
Ophthalmic Physiol Opt 1991 Jan;11(1):16-21.PMID:2034449doi
Cyclopentolate has been widely used as a cycloplegic and mydriatic agent for over 30 years. It has gained widespread use as the cycloplegic drug of first choice for most children over the age of 1 year and allows many optometrists and ophthalmologists to carry out quick, successful cycloplegic refractions with few complications. During this time very few side-effects have been reported with the most commonly used 1% solution. This paper outlines two cases in which a possible allergic-type reaction occurred shortly after the instillation of 1% Cyclopentolate hydrochloride in 'Minims' form (Smith and Nephew). This article also reviews the uses and side-effects of Cyclopentolate and aims to warn practitioners about the possibility of such reactions, ways of avoiding their occurrence and suitable measures to take should they occur.
The effects of tropicamide and Cyclopentolate hydrochloride on laser flare meter measurements in uveitis patients: a comparative study
Int Ophthalmol 2021 Mar;41(3):853-857.PMID:33200390DOI:10.1007/s10792-020-01639-3.
Purpose: To investigate the effects of 1% Cyclopentolate hydrochloride and 1% tropicamide eye drops on aqueous flare measurements by using the laser flare meter. Methods: One hundred forty eight eyes of 83 patients with inactive uveitis were enrolled. The patients were randomly assigned to receive either 1% tropicamide (Group 1) or 1% Cyclopentolate hydrochloride (Group 2) as the mydriatic agent. Best corrected visual acuity (BCVA), intraocular pressure (IOP), aqueous flare reaction levels measured by laser flare meter device (FM 600, Kowa, Kowa Company Ltd, Nagoya, Japan) before and post dilatation agents were evaluated. Results: Group 1 consisted of 75 eyes and Group 2 consisted of 77 eyes. The mean age of Group 1 patients was 34.85 ± 12.60 (range, 12-64) years; the mean age of Group 2 was 36.92 ± 13.30 (range, 12-70) years (p > 0.05). The mean BCVAs of two groups were 0.16 ± 0.43 (range, 0.00-3.10) logMAR and 0.17 ± 0.42 (range, 0.00-3.10) logMAR, respectively. There were no statistically significant differences between Groups 1 and 2 regarding gender or clinical characteristics (p > 0.05). No significant differences were detected in pre- or post-dilatation values between two groups (p = 0.470, p = 0.998). Conclusions: As a result, anterior chamber flare values in uveitis patients do not differ significantly between 1% tropicamide and 1% Cyclopentolate hydrochloride, and both agents can be safely used for dilatation during examination of patients with uveitis.
Delirium due to the use of topical Cyclopentolate hydrochloride
Ideggyogy Sz 2020 Jan 30;73(1-2):51-52.PMID:32057204DOI:10.18071/isz.73.0051.
Introduction - Our aim is to present a rare case where a child had delirium manifestation after instillation of Cyclopentolate. Case presentation - A 7-year old patient was seen in our outpatient clinic, and Cyclopentolate was dropped three times at 10 minutes intervals in both eyes. The patient suddenly developed behavioral disorders along with gait disturbance, and complained of visual hallucinations 20-25 minutes after the last drop. The patient was transferred to intensive care unit and 0.02 mg/kg IV. physostigmine was administered. The patient improved after minutes of onset of physostigmine, and was discharged with total recovery after 30 minutes. Conclusion - Delirium is a rare systemic side effect of Cyclopentolate. The specific antidote is physostigmine, which can be used in severely agitated patients who are not responding to other therapies.